Is Impact BioMedical, Inc. (IBO) overvalued? · rev $18.0K
Impact BioMedical, Inc. (IBO) is a biotechnology company listed on US.
This page asks whether Impact BioMedical, Inc. (IBO) looks expensive on cached numbers — not a short thesis.
Latest reported IBO revenue for 2025-09-30 was $18.0K. Net income was -$1.5M. IBO currently screens at market cap $7.6M.
IBO currently screens at market cap $7.6M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next IBO 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the IBO stock page for the full model, not this heading.
Not investment advice.